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Abstract
Background: Burkholderia cenocepacia is recognized as opportunistic pathogen that can cause lung
infections in cystic fibrosis patients. A hallmark of B. cenocepacia infections is the inability to
eradicate the organism because of multiple intrinsic antibiotic resistance. As Resistance-
Nodulation-Division (RND) efflux systems are responsible for much of the intrinsic multidrug
resistance in Gram-negative bacteria, this study aims to identify RND genes in the B. cenocepacia
genome and start to investigate their involvement into antimicrobial resistance.
Results: Genome analysis and homology searches revealed 14 open reading frames encoding
putative drug efflux pumps belonging to RND family in B. cenocepacia J2315 strain.
By reverse transcription (RT)-PCR analysis, it was found that orf3, orf9, orf11, and orf13 were
expressed at detectable levels, while orf10 appeared to be weakly expressed in B. cenocepacia.
Futhermore, orf3 was strongly induced by chloramphenicol. The orf2 conferred resistance to
fluoroquinolones, tetraphenylphosphonium, streptomycin, and ethidium bromide when cloned and
expressed in Escherichia coli KAM3, a strain lacking the multidrug efflux pump AcrAB. The orf2-
overexpressing  E. coli also accumulate low concentrations of ethidium bromide, which was
restored to wild type level in the presence of CCCP, an energy uncoupler altering the energy of
the drug efflux pump.
Conclusion: The 14 RND pumps gene we have identified in the genome of B. cenocepacia suggest
that active efflux could be a major mechanism underlying antimicrobial resistance in this
microorganism. We have characterized the ORF2 pump, one of these 14 potential RND efflux
systems. Its overexpression in E. coli conferred resistance to several antibiotics and to ethidium
bromide but it remains to be determined if this pump play a significant role in the antimicrobial
intrinsic resistance of B. cenocepacia. The characterization of antibiotic efflux pumps in B.
cenocepacia is an obligatory step prior to the design of specific, potent bacterial inhibitors for the
improved control of infectious diseases. Consequently, the topic deserves to be further
investigated and future studies will involve systematic investigation on the function and expression
of each of the RND efflux pump homologs.
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Background
Bacteria have evolved a variety of strategies to resist anti-
biotics such as enzymatic inactivation, target alteration,
efflux, and permeability changes. Antibiotic resistance can
be intrinsic or acquired. Intrinsic resistance is intimately
associated to the biology of the organism and usually
involves the ability to resist a large number of different
classes of antibiotics, while acquired resistance occurs
when a bacterium that is sensitive to antibiotics develops
resistance by mutation or by acquisition of new DNA. Bac-
terial intrinsic drug resistance was thought to be a passive
mechanism, based on the absence of the drug target or on
the lack of permeability of the bacteria to a given drug.
However, it is becoming increasingly evident that the
intrinsic resistance of many bacteria to antibiotics
depends on the constitutive or inducible expression of
active efflux systems [1,2]. A typical example is Pseu-
domonas aeruginosa, which was long thought to be poorly
susceptible to a large range of antibiotics of different
classes due to the low level of permeability of its outer
membrane to drugs. However, disruption of the gene
encoding the MexB pump dramatically increases the sus-
ceptibility of P. aeruginosa to beta-lactams, tetracyclines,
fluoroquinolones, and chloramphenicol [3], indicating
that the resistance was mediated by efflux.
In the prokaryotic kingdom there are five major families
of efflux transporters: MF (major facilitator), MATE
(multidrug and toxic efflux), RND (resistance-nodula-
tion-division), SMR (small multidrug resistance), and
ABC (ATP binding cassette). All these systems utilize the
proton motive force as an energy source, apart from the
ABC family, which utilizes ATP hydrolysis to drive the
export of substrates [4].
RND transporters exist in all kingdoms of living organ-
isms, but seem to be involved in drug resistance especially
in Gram-negative bacteria [5]. The RND transporters func-
tion as a protein complex spanning from the cytoplasmic
membrane to the outer membrane. The recent resolution
of the three-dimensional structures of TolC and AcrB from
Escherichia coli and MexA and OprM from P. aeruginosa
gave rise to a better understanding of the efflux mecha-
nism in Gram-negative bacteria [6-10].
The efflux pump systems of the RND family are organized
as tripartite efflux pumps. The pump in E. coli and other
gram-negative bacteria has three components: a trans-
porter (efflux) protein in the inner membrane (e.g., AcrB),
a periplasmic accessory protein (e.g., AcrA), and an outer
membrane protein (OMP) channel (e.g., TolC) [11]. AcrB
captures its substrates within either the phospholipid
bilayer of the inner membrane of the bacterial cell enve-
lope or the cytoplasm [12] and transports them into the
external medium via TolC [13]. The cooperation between
AcrB and TolC is mediated by the periplasmic protein
AcrA. The genetic organizations of the genes encoding
these tripartite efflux systems are also similar among dif-
ferent species. Typically, the genes are organized as an
operon: the regulator gene is located adjacent to the gene
encoding the periplasmic accessory protein, which is
located adjacent to the gene encoding the efflux pump
protein, which is located next to that for the OMP. The
membrane fusion protein and the pump protein are usu-
ally cotranscribed. For some systems and/or species, the
OMP is not collocated with the other genes, e.g., E. coli
acrAB and tolC [14] and P. aeruginosa mexXY and oprM
[15].
RND efflux systems are also found in bacteria that exhibit
cell wall properties to P. aeruginosa [16]. The Burkholderia
cepacia complex (Bcc) is noted for their ability to cause
opportunistic infections in humans, particularly in
patients with cystic fibrosis (CF) [17]. Bcc infections of CF
lung can result in asymptomatic carriage, chronic infec-
tion or "cepacia syndrome", which is characterized by a
rapid decline in lung function that can include invasive
disease [18]. The Bcc contains at least nine closely related
species [19,20], of which Burkholderia cenocepacia (origi-
nally B. cepacia genomovar III) is the most prevalent and
has been most commonly associated with epidemic
spread and increased clinical virulence [20,21].
A hallmark of Bcc infections is the inability to eradicate
the organism because of high-level multiple intrinsic anti-
biotic resistance [22].
The multiple antibiotic resistance of Bcc has been attrib-
uted to reduced outer membrane permeability [23-25],
production of modifying enzymes such as β-lactamases
[26], and alteration of antibiotic targets [27]. Much less
information is available on drug efflux systems, and only
a few multi-drug efflux pumps of the MFS and MATE fam-
ilies have been described in Bcc species [28,29]. Screening
for chloramphenicol resistance of a cosmid library con-
structed from a CF clinical isolate allowed the identifica-
tion of the first RND efflux operon in B. cenocepacia [30].
Within this operon, genes encoding a periplasmic lipase-
like protein (llpE), a periplasmic linker (ceoA), a cytoplas-
mic membrane component (ceoB), and an outer mem-
brane protein (opcM) were identified [31]. CeoA, CeoB,
and OpcM have homologs in P. aeruginosa and other
Gram-negative bacteria. A significant difference from
other prokaryotic multidrug efflux systems, including all
RND pumps described to date, is the inclusion of a gene
encoding a lipase-like protein in the B. cenocepacia efflux
operon [31].
Aim of this study was to identify RND genes in the B. cen-
ocepacia genome and start to investigate their involvementBMC Microbiology 2006, 6:66 http://www.biomedcentral.com/1471-2180/6/66
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into antimicrobial resistance. Fourteen homologues of
RND efflux pump genes were identified by in silico homol-
ogy searches. By RT-PCR it was found that some of them
were expressed at detectable levels in not inducing condi-
tion, i.e. growth in LB medium, while others were
detected in inducing conditions, i.e. growth in LB
medium in the presence of an antibiotic. Further, orf2
gene conferred a multidrug resistant phenotype, when
over-expressed in Escherichia coli KAM3 strain. Moreover,
an energy-dependent ethidium bromide efflux was
observed in E. coli KAM3 cells harbouring orf2  gene.
Results and discussion
Analysis of RND drug transporters
The B. cenocepacia J2315 strain was isolated in 1989 in
Edimburgh (UK) from the sputum of a cystic fibrosis
patient [[32], in this reference identified as CF5610]. The
genome sequence of this strain is available within the
Sanger website [33]. To identify the B. cenocepacia drug
efflux proteins belonging to RND, we first scanned the B.
cenocepacia  predicted proteins for the presence of the
transporter family signature characterized by a number of
strongly conserved amino acid residues. The sequences of
the motifs are: motif A (G x s x v T v x F x x g t D x x x A q
v q V q n k L q x A x p x L P x x V q x q g x x v x k), motif B
(a l v l s a V F l P m a f f g G x t G x i y r q f s i T x v s A m
a l S v x v a l t l t P A l c A), motif C (x x x G k x l x e A x x
x a a x x R L R P l L M T s L a f i l G v l P l a i a t G x A G a),
and motif D (S i N t l T l f g l v l a i G L l v D D A l V v V E
N v e R v l a e) [34], where x indicate any amino acid, cap-
ital letters show amino acids most frequently observed in
a single position in more than 70% of the transport pro-
teins, and lowercase letters display amino acid occurring
in more than 40% of RND. By this method, fourteen pos-
sible RND homologues have been identified (here named
ORF1-ORF14). In Table 1, the position of the residues
encompassing the four typical motifs is indicated; it is
noteworthy that the relative distances among the specific
motifs appear well conserved in all the identified proteins.
Members of the RND family have 12 TMS, with two large
loops between TMS1 and TMS2, and TMS7 and TMS8,
respectively [5]. This organization appears well conserved
in all the B. cenocepacia hypothetical RND transporters,
except for ORFs 11 and 14, which present 11 and 10 TMS,
respectively (data not shown). In order to assess a putative
function of the identified transporters, an integrative anal-
ysis of protein motif databases was carried out, by using
the InterProScan program. The proteins ORF1–ORF10
show the ACRIFLAVINRP, a 9-element fingerprint that
provides a signature for members of the acriflavin resist-
ance protein family as AcrB of E. coli [35], while the pro-
teins ORF11–ORF14 show a 6–8 element fingerprint
(Table 1). All hypothetical RNDs contain two transmem-
brane functional domains located within TMS4 and
TMS11 that coincide with the transporter family signature
motifs C and D, respectively (Table 1). The crystal struc-
ture of multidrug efflux transporter AcrB of E. coli [10]
reveals that this protein is characterized by the four sub-
domains PN1, PN2, PC1, and PC2. The structural motifs
PN1 and PN2 comprise the polypeptide segment between
TMS1 and TMS2, while PC1 and PC2 comprise the seg-
ment between TMS7 and TMS8. All the B. cenocepacia
RND transporters (ORF1–ORF14) show the four sub-
domains; the region with subdomains PN1 and PN2 coin-
cides always with the transporter family signature motif A
(Table 1). The TolC docking domain is composed of two
subdomains, DN and DC, and these subdomains are
found in all hypothetical RND proteins except the ORF11
that present only the DC subdomain (Table 1). In order to
obtain a more exhaustive analysis about the structural and
conformational properties of the ORFs, the amino acid
sequences were analysed by Phyre program and the data
were reported in Table 1. The ORF1–14 were compared to
the RND proteins of E. coli and P. aeruginosa by using the
BLASTP program. Particularly, ORF1, ORF2, and ORF4
show strong identity with E. coli AcrB (60%, 64%, 66%,
respectively) and with P. aeruginosa MexB (55%, 63%,
64%, respectively). ORF5 and ORF8 show identity with P.
aeruginosa MexD (50%, 56%, respectively), while ORF9
and ORF10 show identity with P. aeruginosa MexF (56%,
64%, respectively). ORF11 and ORF12 are homologues of
metal efflux transporters belonging to the RND family of
E. coli and P. aeruginosa (data not shown). Particularly,
ORF11 is highly homologous to CzrA protein of P. aerugi-
nosa, involved in cadmium and zinc resistance [36].
Analysis of the upstream and downstream regions of the
RND coding genes confirmed the association with both
an AcrA/MexA homolog and a TolC/OprM homolog in a
variety of arrangements (Figure 1). Indeed, orf1, orf2, orf3,
orf4, orf8, orf9, orf10 (ceoB), orf11, orf12, orf13, and orf14
seem to be part of an operon that also included a mexA
and an oprM homologs, thus containing all three of the
components of the tripartite pump complex. Differently,
orf5  appears to have only the membrane component,
while orf6 and orf7 are apparently co-transcribed and in
operon with a periplasmic membrane fusion protein (Fig-
ure 1). In P. aeruginosa, the genes encoding the RND trans-
porter (MexB homolog) and periplasmic membrane
fusion protein (MexA homolog) are always present, while
the gene encoding the OM channel (OprM homolog) is
not always present [37]. In E. coli, the genes for transporter
and membrane fusion proteins (acrAB) occur together as
an operon and the gene for the TolC occurs elsewhere on
the genome [37]. In B. cenopacia the genetic organization
of the RND orfs seems to resemble in part that of P. aeru-
ginosa and in part that of E. coli. As AcrD pump of E. coli,
orf5 seem to be transcribed alone in the genome of B. cen-
ocepacia  [38], while orf6  and  orf7  are organized as theB
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Table 1: Predicted functional motifs for ORF1-ORF14 of B. cenocepacia
RND CONSERVED 
MOTIFS
FUNCTIONAL MOTIFS STRUCTURAL 
ANALYSIS
ORFsa Motif s Ab, Bb, Cb, Db Acriflavin resistance protein 
domains (ACRIFLAVINRP)c
AcrB transmem-
brane domainc
AcrB pore domain 
(PN1, PN2, PC1, 
PC2 subdomains)c
AcrB/TolC dock-
ing domain (DN, 
DC subdomains)c
Familyd
BCAS0592 ORF1 
Chromosome 3
38–134, 445–493, 826–
1051, 272–503
8–32, 36–54, 336–359, 363–384, 391–
415, 445–468, 470–493, 552–569, 
620–634
272–503, 826–1051 38–134, 565–669 182–271, 720–825 Multidrug efflux 
transporter AcrB pore 
domain
BCAS0765 ORF2 
Chromosome 3
38–134, 445–493, 809–
1035, 272–503
8–32, 36–54, 336–359, 363–384, 391–
415, 445–468, 470–493, 553–570, 
622–636
272–503, 809–1035 38–134, 566–672 182–271, 723–808 Multidrug efflux 
transporter AcrB 
transmembrane domain
BCAL1675 ORF3 
Chromosome 1
38–133, 444–492, 804–
1027, 271–502
8–32, 36–54, 335–358, 362–383, 390–
414, 444–467, 469–492, 551–568, 
618–632
271–502, 804–1027 38–133, 564–668 719–803, 181–270 Multidrug efflux 
transporter AcrB 
transmembrane domain
BCAL2821 ORF4 
Chromosome 1
38–134, 445–493, 809–
1035, 272–503
8–32, 36–54, 336–359, 363–384, 391–
415, 445–468, 470–493, 553–570, 
622–636
272–503, 809–1035 38–134, 566–672 182–271, 723–808 Multidrug efflux 
transporter AcrB 
transmembrane domain
BCAL1778 ORF5 
Chromosome 1
40–136, 446–494, 812–
1037, 274–504
10–34, 38–56, 338–361, 365–386, 
393–417, 446–469, 471–494, 562–579, 
629–643
274–504, 812–1037 40–136, 575–676 184–273, 727–811 Multidrug efflux 
transporter TolC docking 
domain
BCAL1079 ORF6 
Chromosome 1
40–136, 438–486, 792–
1019, 266–496
10–34, 38–56, 330–353, 357–378, 
385–409, 438–461, 463–486, 543–560, 
610–624
266–496, 792–1019 40–136, 556–656 189–265, 707–791 Multidrug efflux 
transporter AcrB pore 
domain
BCAL1080 ORF7 
Chromosome 1
40–134, 438–486, 853–
1084, 266–496
10–34, 38–56, 330–353, 357–378, 
385–409, 438–461, 463–486, 544–561, 
607–621
266–496, 853–1084 40–134, 557–653 183–265, 704–776 Multidrug efflux 
transporter AcrB pore 
domainB
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BCAM0926 ORF8 
Chromosome 2
38–134, 445–493, 803–
1027, 272–503
8–32, 36–54, 336–359, 363–384, 391–
415, 445–468, 470–493, 552–569, 
619–633
272–503, 803–1027 38–134, 565–667 182–271, 718–802 Multidrug efflux 
transporter AcrB pore 
domain
BCAM1946 ORF9 
Chromosome 2
40–136, 447–495, 814–
1041, 275–505
10–34, 38–56, 339–362, 366–387, 
394–418, 447–470, 472–495, 562–579, 
631–645
275–505, 814–1041 40–136, 575–678 185–274, 729–813 Multidrug efflux 
transporter TolC docking 
domain
BCAM2550 ORF10 
Chromosome 2
40–136, 447–495, 817–
1043, 275–505
10–34, 38–56, 339–362, 366–387, 
394–418, 447–470, 472–495, 562–579, 
631–645
275–505, 817–1043 40–136, 575–681 185–274, 732–816 Multidrug efflux 
transporter AcrB pore 
domain
BCAM0713 ORF11 
Chromosome 2
42–135, 480–503, 822–
1049, 167–513
12–36, 40–58, 339–362, 366–387, 
480–503, 553–570
167–513, 822–1049 42–135, 566–673 726–821 Multidrug efflux 
transporter TolC docking 
domain
BCAM0435 ORF12 
Chromosome 2
42–135, 454–502, 807–
1043, 269–511
12–36, 40–58, 334–357, 361–382, 
389–413, 552–569
269–511, 807–1043 42–135, 565–610 185–268, 722–806 Multidrug efflux 
transporter AcrB pore 
domain
BCAL1811 ORF13 
Chromosome 1
49–146, 446–494, 805–
1029, 274–504
47–65, 339–362, 393–417, 446–469, 
471–494, 554–571
274–504, 805–1029 49–146, 567–677 192–273, 721–804 Multidrug efflux 
transporter AcrB pore 
domain
BCAS0582 ORF14 
Chromosome 3
40–136, 438–486, 832–
1060, 266–496
10–34, 38–56, 330–353, 357–378, 
385–409, 438–461, 463–486, 551–568
266–496, 832–1060 40–136, 564–675 183–265, 727–831 Multidrug efflux 
transporter AcrB pore 
domain
aAs reported by the web site: http://www.sanger.ac.uk/Projects/B_cenocepacia/; bMotifs derived from the BLAST SEARCH program at the web site: http://www.sanger.ac.uk/Projects/B_cenocepacia/
; cResults from the web site: http://www.ebi.ac.uk/InterProScan/; dResults from the web site: http://www.sbg.bio.ic.ac.uk/~phyre/.
Table 1: Predicted functional motifs for ORF1-ORF14 of B. cenocepacia (Continued)BMC Microbiology 2006, 6:66 http://www.biomedcentral.com/1471-2180/6/66
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genes PA2526-2527-2528 of P. aeruginosa that contains an
additional RND transporter [39]. Many pump compo-
nent-encoding operons contain a physically linked regula-
tory gene coding for either a repressor or an activator [40].
For example, expression of the mexAB-oprM operon is reg-
ulated by the product of the upstream and divergently
transcribed mexR gene. Not surprisingly, clinical isolates
that overexpress the MexAB-OprM system often carry
mutations in the mexR gene [41]. In the case of orf1, orf2,
orf4, orf6–7, orf9, orf10, orf13, and orf14 a hypothetical reg-
ulatory gene has been identified, divergently transcribed
for all genes, except for the hypothetical operon contain-
ing the orf2, orf4, and orf6–7, respectively (Figure 1). The
WEBSIDD program was used to analyse sequences
encompassing the coding and intergenic regions of the
hypothetical RND operons for the presence of SIDD
(Stress Induced Duplex Destabilization) sites. These sites
have a specific and statistically highly significant pattern
of association with transcriptional regions, specifically
with promoters because strand separation is a necessary
step in the initiation of transcription [42]. All the ORFs
present SIDD sites localized upstream of the first gene of
the entire operon, except for the orf5.
RT-PCR analysis of the B. cenocepacia genes coding for 
the RND transporters
We found 14 genes codifying hypothetical RND drug
transporters into B. cenocepacia genome. By RT-PCR anal-
ysis, we studied the expression of all these genes at the
exponential phase of cells grown in LB medium. A clear
expression of orf3, orf9, orf11, and orf13 was observed (Fig-
ure 2A, lanes 1, 4, 8,10), while orf10  appeared to be
weakly expressed (Figure 2A, lane 6). The expression of
the other orfs (orf1, orf2, orf4, orf5, orf6–7, orf8, orf12, and
orf14) was not detectable, at least in our conditions (data
not shown).
It has been demonstrated that orf10 corresponds to the
previously described ceoB gene belonging to ceo operon,
which has been shown to be strongly induced by salicylate
and chloramphenicol [31]. We decide to evaluated the
expression of the 14 genes in B. cenocepacia cells grown in
the presence of chloramphenicol (inducing conditions).
In B. cenocepacia J2315 strain, the basal level of expression
of the orf3 (Figure 2A, lane 1) was strongly increased by
chloramphenicol (Figure 2A, lane 2). No induction could
be detected in the case of orf1, orf2, orf4, orf5, orf6–7, orf8,
orf12, and orf14  (data not shown) and no increased
expression could be observed in the case of orf9, orf10,
orf11, and orf13 (data not shown). However, the B. ceno-
cepacia rRNA 16S expression was not affected by different
growth conditions (Figure 2B, lanes 1 and 2), thus dem-
onstrating that the differences detected in the amount of
orf3 mRNA, under different growth conditions, are genu-
ine.
As the ceo operon has been discovered as responsible for
the MDR phenotype of a clinical strain [31], we can
hypothesize that this RND efflux system is expressed as a
result of a mutation. In our conditions, no transcriptional
induction of orf10 could be detected also in the presence
of salicylate (data not shown).
ORF3 showed 71% identity with P. aeruginosa MexY, an
inducible efflux system that contributes to the natural
resistance of P. aeruginosa to antibiotics [43]. Experiments
involving real-time PCR in P. aeruginosa PAO1 showed
induction of gene mexY by chloramphenicol, tetracycline,
macrolides, and aminoglycosides [44]. To date, no infor-
Proposed RND efflux pump encoded by B. cenocepacia  genome Figure 1
Proposed RND efflux pump encoded by B. cenocepa-
cia genome. The organization of the RND efflux pump 
genes identified in B. cenocepacia genome was achieved by 
bioinformatic tools as described in Methods. RND trans-
porter-encoding genes are depicted as grey arrows (orf1–
orf14), outer-membrane factor-encoding genes as white 
arrows, periplasmic membrane fusion protein-encoding 
genes as black arrows, and regulatory genes as arrows with 
stripes. Black lines indicate the regions of Stress-Induced 
DNA duplex Destabilization that could be associated with 
promoters. Genes encoding protein components of CeoAB-
OpcM (6) are indicated as white arrow (opcM), grey arrow 
(ceoB), black arrow (ceoA); arrows with stripes and squares 
indicated the ceoR and llpE genes encoding a regulator and a 
putative periplasmic lipase-like protein, respectively.BMC Microbiology 2006, 6:66 http://www.biomedcentral.com/1471-2180/6/66
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mation is available on the regulation of mexXY expression,
except that mutations occurring in the divergently tran-
scribed repressor gene mexZ are frequently isolated from
the sputa of cystic fibrosis patients [45]. In P. aeruginosa,
with the exception of MexAB-OprM, the expression of
most of the RND efflux systems is tightly regulated and
overexpression of these RND pumps is usually caused by
mutations in genes encoding regulatory proteins [39].
Notably, overexpression of multidrug resistance pumps in
clinical isolates of P. aeruginosa, resulting in increased bac-
terial resistance, is usually due to mutations in these regu-
latory genes [46,47]. It would be interesting to further
investigate if the expression of orf3, orf9, orf11, and orf13
is due to a constitutive expression or to a transcriptional
deregulation in the B. cenocepacia clinical isolate analysed
in this study, which showed a multidrug resistance pheno-
type as it is resistant to ampicillin and aztreonam (>2048
μg/ml), ceftazidime (768 μg/ml), meropenem (64 μg/
ml), piperacillin (768 μg/ml) amikacin (64 μg/ml), nor-
floxacin (32 μg/ml), rifampicin (256 μg/ml), streptomy-
cin (>2048 μg/ml), tetracycline (128 μg/ml),
chloramphenicol (32 μg/ml), and gentamicin (1536 μg/
ml).
Cloning and phenotypic analysis of B. cenocepacia orf2 
into E. coli KAM3
One approach to test the role of the identified genes in
drug efflux is to clone them into suitable hosts by selecting
on different compounds. In spite of several attempts, we
met many problems in cloning experiments since a lot of
rearranged clones were found in the host strains (E. coli
and B. multivorans). The difficulties that we met in cloning
experiments could rely both on plasmid instability and/or
toxic effect of the gene product (data not shown). In fact,
the failure could be due to the toxicity of the gene product
for the host bacterial cells and still B. multivorans as a host
causes many troubles (i.e. recombinations, overlapping
with existing pumps, etc.).
Expression of genes coding for the RND proteins from B. cenocepacia Figure 2
Expression of genes coding for the RND proteins from B. cenocepacia. Expression of genes coding for the RND pro-
teins was evaluated by RT-PCR of RNA isolated from B. cenocepacia cultures grown in the LB standard medium without and 
with chloramphenicol. A) Lane M represents the molecular weight marker (Fermentas), whose sizes of some bands in base 
pairs (bp) are provided on the left; lanes 3, 5, 7, 9, and 11 represent positive controls, i.e. genomic DNA amplification with 
primers specific for orf3, orf9, orf10, orf11, and orf13 (Table 3); lanes 1 and 2 represent RT-PCR amplification of orf3 in the 
absence and in the presence of 12.8 μg/ml (0.4X MIC) of chloramphenicol, respectively; lanes 4, 6, 8, and 10 represent RT-PCR 
amplifications of orf9, orf10, orf11, and orf13, without antibiotic, respectively; lane CT represents the PCR reaction negative 
control. B) Lanes 1 and 2 represent the expression of rRNA 16S gene in the presence or in the absence of chloramphenicol, 
respectively; lane 3 represents the positive control, i.e. genomic DNA amplification with primers specific for rRNA 16S gene; 
lane M represents the molecular weight marker (Fermentas), whose sizes of some bands in base pairs (bp) are provided on the 
right.
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To overcome this problem we used the E. coli KAM3 strain
as host, which lacks the acrAB genes and is sensitive to
many drugs that are known as substrates of the AcrAB sys-
tem [48]. We decided to characterize one of the 14 hypo-
thetical drug efflux pumps of B. cenocepacia by cloning the
orf2-coding region from B. cenocepacia genomic DNA into
pBAD202 expression vector. The pBAD202 vector and the
recombinant plasmid (pBAD/orf2) were transformed into
E. coli KAM3. We chose ORF2 because of its high homol-
ogy to MexB, responsible for antibiotic resistance in many
Pseudomonas clinical isolates [3]. Particularly, studies with
mutants that overproduce or lack MexAB-OprM demon-
strated that this efflux system extrudes quinolones, mac-
rolides, tetracycline, chloramphenicol, novobiocin, and
most β-lactams but not imipenem [3,49].
The MICs of E. coli KAM3 strains harbouring pBAD202
and pBAD/orf2, respectively, were determined by streak-
ing the cultures onto LB containing different concentra-
tions of the following compounds: streptomycin,
ethidium bromide, nalidixic acid, several quinolones
(ciprofloxacin, ofloxacin, norfloxacin, and sparfloxacin),
chloramphenicol, erythromycin, tetraphenylphospho-
nium, and tetracycline. Plates were incubated at 37°C for
3 days and the growth was visually evaluated. Compared
to the control strain, the overexpression of orf2 into E. coli
KAM3 cells conferred resistance to streptomycin (16X
MIC), tetraphenylphosphonium (8X MIC), ethidium bro-
mide (4X MIC), nalidixic acid (4X MIC), ciprofloxacin
(4X MIC), ofloxacin (2X MIC), and norfloxacin (2X MIC)
(Table 2). No difference in drug susceptibility was found
with sparfloxacin, chloramphenicol, erythromycin, and
tetracycline (data not shown). These data suggest that orf2
is expressed and functional in E. coli KAM3. Interestingly,
in P. aeruginosa, it has been found that fluoroquinolones
like nalidixic acid and norfloxacin can commonly select
mutants that constitutively overproduce the MexAB-
OprM efflux pump system [46].
From these data it appeared that streptomycin and nor-
floxacin could be substrates of ORF2. We decided to per-
form RT-PCR of B. cenocepacia grown in the presence of
sub-inhibitory concentration of streptomycin (204.8 μg/
ml) and norfloxacin (3.2 μg/ml). In our condition, orf2
transcript could not be detected by RT-PCR (data not
shown). The expression of orf2  was also evaluated by
Southern blotting of the RT-PCR agarose gel and subse-
quent hybridization with a labelled 511-bp fragment
internal to orf2 coding region. No hybridisation signals
were observed (data not shown), indicating that orf2 is
not expressed following treatment of B. cenocepacia cells
with streptomycin or norfloxacin.
Three different hypotheses could be given to explain the
fact that orf2  is not expressed. First, the experimental
approaches utilized in this work (RT-PCR and Southern
hybridization analysis) are not enough sensitive to detect
very small amount of orf2 mRNA. Real-time PCR is an
attractive method for estimating gene expression of efflux
pumps in bacteria because of its great sensitivity and wide
effective range. Recently, the real-time PCR appeared to be
a useful alternative method for assessing the expression of
efflux pumps MexB and MexY in P. aeruginosa [50]. Sec-
ond, not all ORF2 substrates in E. coli necessarily must be
inducers of the expression of this pump in B. cenocepacia.
A relevant example of such a behaviour is given by the
MexCD-OprJ efflux pump of P. aeruginosa, which extrudes
antibiotics that do not induce its expression [51]. Instead,
expression of this efflux system was induced by clinical
important disinfectants such as benzalkonium chloride
and chlorhexidine gluconate [51]. Finally, the orf2 expres-
sion may occur in a phase of cellular growth different
from the exponential one we tested. In conclusion, we
could not determined neither the real inducing agent nor
the culture conditions in which induction of orf2 expres-
sion is triggered; therefore, it could be interesting to test
other organic compounds for the ability to induce expres-
sion of this efflux pump.
Ethidium bromide efflux activity
Ethidium bromide efflux experiment was performed to
determine whether E. coli KAM3 cells, carrying the recom-
binant plasmid pBAD/orf2, were more resistant to this dye
due to an active efflux mechanism.
As shown in Figure 3, cells harboring the cloning vector
pBAD202 take up ethidium bromide rapidly and achieve
Table 2: MIC (μg/ml) of drugs for E. coli KAM3 cells transformed with pBAD202 and pBAD/orf2 plasmids
pBAD202 pBAD/orf2
Streptomycin 0.5 8 (16X)
Tetraphenylphosphonium 43 2  ( 8 X )
Ethidium bromide 83 2  ( 4 X )
Nalidixic acid 0.25 1 (4X)
Norfloxacin 0.0125 0.025 (2X)
Ofloxacin 0.002 0.004 (2X)
Ciprofloxacin 0.001 0.004 (4X)BMC Microbiology 2006, 6:66 http://www.biomedcentral.com/1471-2180/6/66
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a steady-state level of accumulation within about 5 min of
incubation.
As observed in several experiments, accumulation of
ethidium bromide was approximately 20% lower when
cells contained the pBAD/orf2 recombinant plasmid.
A reduced level of accumulation of the drug may be
caused either by a decreased level of drug permeation or
by active drug extrusion through the cytoplasmic mem-
brane. To study the effect of membrane deenergization on
the uptake of tetracycline, the protonophore carbonyl cya-
nide m-chlophenylhydrazone (CCCP) was added to cells
containing ethidium bromide. Upon the addition of
CCCP, the level of ethidium bromide accumulation
increased in the case of the pBAD/orf2-harboring strain
and reached a level almost equal to that observed in the
case of the strain containing only the cloning vector
pBAD202 (Figure 3). On the contrary, under our condi-
tions, CCCP had no significant effect on the level of ethid-
ium bromide accumulation in the strain carrying the
cloning vector (Figure 3). These data indicate that ORF2
pumped out ethidium bromide in an energy-dependent
process, presumably by using proton motive force. We
could conclude that ORF2, belonging to RND transport-
ers, is an efflux pump of B. cenocepacia J2315.
Conclusion
Pulmonary infection with Bcc in patients with CF is often
associated with a more rapid decline in lung function.
Because of the resistance of Bcc to many antibiotics, treat-
ment options are often limited.
The emergence of active efflux as a major causative factor
in antibiotic resistance has been one of the most signifi-
cant trend in anti-infective chemotherapy over the last
decade and strategies to identify efflux pump inhibitors
are in progress [52]. For these reasons, the identification
and the characterization of such efflux systems in B. ceno-
cepacia are a very important topic in the field of antibiotic
resistance.
Taken together the results described in this paper fit with
the prediction that B. cenocepacia contains homologs of
the P. aeruginosa Mex-Opr efflux pump systems. Moreo-
ver, orf3, orf9, orf11, and orf13 are expressed in B. cenoce-
pacia J2315, even if, at this stage, it is not possible to state
if this expression is constitutive or due to mutations in
regulatory genes.
Finally, the results described in this paper suggested that
at least one of the RND-type efflux pumps identified,
extrude out of the cell some antibiotics as well as other
compounds (e.g. ethidium bromide). To demonstrate
that this pump is really involved in the multidrug resistant
phenotype of the B. cenocepacia J2315, further studies are
necessary. The generation of mutants with pump overpro-
duction and/or genetic deletion of genes encoding pumps
in a controlled laboratory environment provides invalua-
ble information on the potential impact of multidrug
efflux pumps on the intrinsic resistance of B. cenocepacia
J2315. Because of the difficulties in cloning and expres-
sion experiments, knock-out approach represents the only
alternative method to physiologically characterize these
transporters and to confirm if the encoded pumps play a
significant role in the antimicrobial resistance of this
microorganism.
Accumulation of ethidium bromide in E. coli KAM3 cells har- bouring pBAD202 and pBAD/orf2 Figure 3
Accumulation of ethidium bromide in E. coli KAM3 
cells harbouring pBAD202 and pBAD/orf2. E. coli 
KAM3 cells containing the cloning vector pBAD202 and the 
recombinant plasmid pBAD/orf2 were grown in LB medium 
at 37°C and treated as described in Methods. Ethidium bro-
mide was added to cell suspensions carrying pBAD202 () 
or pBAD/orf2 (), at a final concentration of 20 μM whereas 
the efflux inhibitor CCCP was added 9 min after the addition 
of ethidium bromide at a final concentration of 30 μM. The 
experimental error bars showed standard deviations of tripli-
cate determinations.B
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Table 3: Primers used in this study
Primer Sequence of primers Comments Product size (bp)
2pbadFOR 5'-CACCATGGCCAAGTTCTTTATC-3' Sense primer for the cloning of orf2-coding into pBAD202 3192
2pbadREV 5'-TTACTGCCCCTTCGAATCGTTT-3' Antiense primer for the cloning of orf2-coding into pBAD202
1rtFOR 5'-CCACGCCGTTCGTTCGCATCT-3' Sense primer for RT-PCR analysis of orf1 577
1rtREV 5'-GCTTGGCGAACCACCGGTTGA-3' Antisense primer for RT-PCR analysis orf1
2rtFOR 5'-CGAAGCTGAAGCCGTTGAC-3' Sense primer for RT-PCR analysis orf2 511
2rtREV 5'-TCGTGCTGTCGGCGGTGTT-3' Antisense primer for RT-PCR analysis orf2
3rtFOR 5'-CGCGCTCACCGACCTGATGTT-3' Sense primer for RT-PCR analysis orf3 531
3rtREV 5'-AGCGCGAGGAACACGACGAGC-3' Antisense primer for RT-PCR analysis orf3
4rtFOR 5'-AACATCCTGCGCTGAAGGTCAAC-3' Sense primer for RT-PCR analysis orf4 537
4rtREV 5'-TGACAGCCCCTCTTCCGCCATCAC-3' Antisense primer for RT-PCR analysis orf4
5rtFOR 5'-TACGTGCTGCGCGAACTGAAG-3' Sense primer for RT-PCR analysis orf5 594
5rtREV 5'-AACAGCCACATCACGCAAAACAC-3' Antisense primer for RT-PCR analysis orf5
6rtFOR 5'-TCGAATGGGTGCTGAACCGC-3' Sense primer for RT-PCR analysis orf6 477
6rtREV 5'-CGAATTCTTCCGAGTTGGGGCT-3' Antisense primer for RT-PCR analysis orf6
8rtFOR 5'-CAAGGTCGTGACCGGCGTGTA-3' Sense primer for RT-PCR analysis orf8 517
8rtREV 5'-GATCATCGACAGCACCATCAGC-3' Antisense primer for RT-PCR analysis orf8
9rtFOR 5'-CTATTCGATCAATACGCTCACG-3' Sense primer for RT-PCR analysis orf9 493
9rtREV 5'-CGCATAGACGGCGAACACCAC-3' Antisense primer for RT-PCR analysis orf9
10rtFOR 5'-AACTCGCTGCAGATCTCGGAC-3' Sense primer for RT-PCR analysis orf10 521
10rtREV 5'-ATCGCGAACTGCTTGTAGAACTG-3' Antisense primer for RT-PCR analysis orf10
11rtFOR 5'-TCGCGGCGAAGATGGAGGAC-3' Sense primer for RT-PCR analysis orf11 522
11rtREV 5'-TCGTCGCCATCGGATGGAACAT-3' Antisense primer for RT-PCR analysis orf11
12rtFOR 5'-CGCGCTCAACGACTGGTTCCT-3' Sense primer for RT-PCR analysis orf12 520
12rtREV 5'-CAGTTGCGATCGGTCGTAGGTC-3' Antisense primer for RT-PCR analysis orf12
13rtFOR 5'-CAGGTTACACAGATGCGAACGA-3' Sense primer for RT-PCR analysis orf13 530
13rtREV 5'-AAGCCCGACACGTGACGAGCG-3' Antisense primer for RT-PCR analysis orf13
14rtFOR 5'-ACGCCGACCGACATCTTTCCG-3' Sense primer for RT-PCR analysis orf14 615
14rtREV 5'-CTGCGTGCTGCCGTTCATCTGC-3' Antisense primer for RT-PCR analysis orf14
15rtFOR 5'-AGAGTTTGATCATGGCTCAG-3' Sense primer for RT-PCR analysis rRNA 16S gene 1490
16rtREV 5'-TACCTTGTTACGACTTCAC-3' Antisense primer for RT-PCR analysis rRNA 16S geneBMC Microbiology 2006, 6:66 http://www.biomedcentral.com/1471-2180/6/66
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A greater understanding of the genetic determinants that
play a role in antibiotic resistance will lead to the develop-
ment of new strategies for the treatment of B. cenocepacia
infections in patients with cystic fibrosis.
Methods
Computer methods
The B. cenocepacia J2315 genome sequence data were pro-
duced by the B. cenocepacia Sequencing Group at the
Sanger Institute and it was retrieved from the Sanger FTP
Server [53]. This analysis integrates different approaches
and is based on the conservation of three features among
drug transporters in microorganisms: specific sequence
motifs, overall sequence similarity, and structural similar-
ities.
Searches of the stretches of amino acids containing the
specific motifs conserved in members of the RND trans-
porters among the B. cenocepacia proteins were done using
the BLAST SEARCH program provided at the Sanger web-
site [33]. To well characterize the specific motifs present in
the B. cenocepacia transporters, the regions containing the
motifs were aligned using the CLUSTALW program within
the EBI website [54]. Searches of sequence similarity
between potential drug transporters and proteins charac-
terized in E. coli and P. aeruginosa were done using the
BLASTP program within the NCBI website [55]. The
number and the position of the transmembrane domains
(TMS) have been predicted by TMHMM program within
the CBS website [56]. All the identified hypothetical RND
proteins were analysed by InterProScan program provided
by the EBI website [54] and Phyre program provided by
the SBG website [57]. InterPro is a database of protein
families, domains, and functional sites in which identifi-
able features found in known proteins can be applied to
unknown protein sequences; the Phyre automatic fold
recognition server predicts the structure and/or function
of unknown protein sequences.
The analysis for the presence of duplex destabilized motifs
in sequences containing the intergenic and coding regions
encompassing RND genes were done using WEBSIDD
program within the Genome Center website [58]. This
program uses an algorithm that allows to identify regions
of Stress-Induced DNA duplex Destabilization (SIDD)
that could be associated with promoters [59].
Growth conditions, plasmids, and cloning procedures
Escherichia coli KAM3 and Burkholderia cenocepacia J2315
strains were grown on Luria Bertani agar or broth (LB)
medium at 37°C. E. coli KAM3 cells harbouring pBAD202
and pBAD/orf2 plasmids were grown in the presence of
kanamycin (50 μg/ml) (Sigma).
B. cenocepacia J2315 genomic DNA was isolated as
described previously by Scordilis et al. [60].orf2  was
amplified by PCR from B. cenocepacia J2315 genomic
DNA, by using the 2pbadFOR and 2pbadREV primers
indicated in Table 3. The CACC sequence was introduced
at 5' terminus of the primer 2pbadFOR to directionally
clone the PCR product in the correct orientation into
pBAD202 expression vector (as described by "pBAD direc-
tional TOPO expression kit" of Invitrogen).
The PCR reaction was carried out as follows by using Accu-
Prime Pfx DNA polymerase (Invitrogen): initial denatura-
tion at 95°C for 3 min; 35 cycles of denaturation at 95°C
for 30 sec, annealing at 52°C for 1 min, extension at 68°C
for 4 min and final extension at 68°C for 10 min. PCR
products were analysed by electrophoresis on 1% agarose
gel, containing 0.5 μg/ml of ethidium bromide and visu-
alized under UV light.
The orf2 PCR product was cloned into pBAD202 expres-
sion vector and transformed into E. coli Top10 competent
cells (Invitrogen). Plasmid DNA, isolated by the alkaline
lysis method [61], was sequenced to be sure that no muta-
tions were introduced in the amplified product and intro-
duced into E. coli KAM3 strain by electroporation.
RT-PCR
RT-PCR was used to monitor gene expression. B. cenocepa-
cia J2315 strain was grown to O.D.600 = 0.3 in LB broth. To
detect if gene expression was induced by some substrates,
cells were grown in the presence of chloramphenicol at a
final concentration of 12.8 μg/ml (0.4X MIC), streptomy-
cin at a final concentration of 204.8 μg/ml (0.1X MIC),
and norfloxacin at a final concentration of 3.2 μg/ml
(0.1X MIC). Total RNA was extracted using the RNeasy
Mini Kit (Qiagen), according to the manufacturer's proto-
col. 1 μg of RNA was treated with 10 U of DNase I-RNase
free (Roche) for 30 min at room temperature and then
heated at 70°C for 10 min. The RT reactions were carried
out, by using 2 μg of template RNA in the presence of M-
MLV Reverse Transcriptase (Promega) and specific gene
primers (Table 3). Reverse transcription was carried out as
follows: (a) 2 μg of RNA and 0.5 μg of each downstream
primer were incubated at 70°C for 5 min and then cooled
on ice; (b) 5 μl of 5X reaction buffer, 5 μl of 10 mM
dNTPs, and 200 U of M-MLV enzyme were added and the
reaction was carried out at 37°C for 1 h; (c) the enzyme
was inactivated at 95°C for 5 min and the reaction was
ethanol-precipitated. The cDNA was dissolved in 20 μl of
deionised water and 4 μl were used as template with the
gene-specific primers (Table 3) for PCR amplification, by
using RedTaq genomic DNA polymerase (Sigma). The
PCR reaction was carried out as follows: initial denatura-
tion at 94°C for 3 min; 25 cycles of denaturation at 94°C
for 1 min, annealing at 54°C, 62°C, 64°C, 66°C or 68°CBMC Microbiology 2006, 6:66 http://www.biomedcentral.com/1471-2180/6/66
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depending on the primer for 1 min, extension at 72°C for
1 min, and final extension at 72°C for 10 min. RT-PCR
products were analysed by electrophoresis on 1.5% agar-
ose gel, containing 0.5 μg/ml of ethidium bromide and
visualized under UV light. The same reactions were carried
out for each sample without M-MLV Reverse Transcriptase
to ensure that amplification was a result of cDNA and not
of contaminating DNA molecules. In all experiments, the
expression of rRNA 16S gene was determined as an inter-
nal control to ensure that the differences observed in
genes expression were not due to variability in the RNA
isolation and/or in the RT-PCR technique.
Southern blotting was performed as described by Sam-
brook and Russell [61]; a 511-bp fragment internal to orf2
coding region was labelled with [α-32P] dCTP 3000 Ci
mmol-1 (Amersham Biosciences) by using the HexaLabel
Plus DNA Labelling Kit (Fermentas) according to the
manufacturer's instructions.
MIC determinations
Determination of MIC for E. coli KAM3, transformed with
recombinant plasmids, was performed by streaking 1 ×
105 cells onto LB agar containing different concentrations
of drugs. The following compounds were tested: strepto-
mycin, ethidium bromide, nalidixic acid, several quinolo-
nes (ciprofloxacin, ofloxacin, norfloxacin, and
sparfloxacin), chloramphenicol, tetraphenylphospho-
nium erythromycin, and tetracycline. Plates were incu-
bated at 37°C for 3 days and the growth was visually
evaluated.
Determination of MIC for B. cenocepacia J2315 strain was
performed by streaking 1 × 105 cells onto LB containing
different concentrations of drugs. Plates were incubated at
37°C for about 3 days and the growth was visually evalu-
ated. The following antibiotics were tested to determine
the resistance profile: ampicillin, amikacin, aztreonam,
ceftazidime, chloramphenicol, gentamicin, meropenem,
norfloxacin, piperacillin, tetracycline, streptomycin, and
rifampicin.
The MIC is defined as the lowest concentration of drug
that prevented visible growth. The results are the averages
of three replicates.
Ethidium bromide accumulation assay
E. coli KAM3 cells harbouring pBAD202 and pBAD/orf2
plasmids were grown in LB medium in the presence of
kanamycin (50 μg/ml) under aerobic conditions at 37°C.
Bacteria were harvested at the esponential phase of
growth, washed twice with a minimal medium [76 mM
(NH4)2SO4, 500 mM KH2PO4, pH 7.0, 1 mM MgSO4,
0.4% glucose], and resuspended in the same medium to
an O.D.650 of 0.2. Ethidium bromide was added to cells to
a final concentration of 20 μM and the change in fluores-
cence intensity was continuously monitored at excitation
and emission wavelengths of 500 and 580 nm, respec-
tively. Fluorescence intensity is proportional to the quan-
tity of intracellular dye, since ethidium bromide
fluorescence is enhanced by the binding to intracellular
components, especially to nucleic acids.
The efflux pumps inhibitor carbonyl cyanide m-chlophe-
nylhydrazone (CCCP) was added to the cells suspensions
to a final concentration of 30 μM after 9 min of the addi-
tion of ethidium bromide, to assess energy-dependent
efflux.
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